CN102548539A - 用于治疗癌症和其它疾病或病症的医药组合物 - Google Patents

用于治疗癌症和其它疾病或病症的医药组合物 Download PDF

Info

Publication number
CN102548539A
CN102548539A CN2010800415230A CN201080041523A CN102548539A CN 102548539 A CN102548539 A CN 102548539A CN 2010800415230 A CN2010800415230 A CN 2010800415230A CN 201080041523 A CN201080041523 A CN 201080041523A CN 102548539 A CN102548539 A CN 102548539A
Authority
CN
China
Prior art keywords
medical composition
formula
composition according
pharmaceutically acceptable
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800415230A
Other languages
English (en)
Chinese (zh)
Inventor
维贾亚拉克希米·拉马南
艾琳·索菲·托拜厄斯
当特尔·施佩希特·费韦斯
雷蒙德·D·斯科尔奇恩斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102548539(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to CN201410112836.0A priority Critical patent/CN103893186B/zh
Publication of CN102548539A publication Critical patent/CN102548539A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
CN2010800415230A 2009-07-31 2010-07-28 用于治疗癌症和其它疾病或病症的医药组合物 Pending CN102548539A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410112836.0A CN103893186B (zh) 2009-07-31 2010-07-28 用于治疗癌症和其它疾病或病症的医药组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23021209P 2009-07-31 2009-07-31
US61/230,212 2009-07-31
PCT/US2010/002109 WO2011014248A1 (en) 2009-07-31 2010-07-28 Pharmaceutical compositions for the treatment of cancer and other diseases or disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410112836.0A Division CN103893186B (zh) 2009-07-31 2010-07-28 用于治疗癌症和其它疾病或病症的医药组合物

Publications (1)

Publication Number Publication Date
CN102548539A true CN102548539A (zh) 2012-07-04

Family

ID=42697590

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800415230A Pending CN102548539A (zh) 2009-07-31 2010-07-28 用于治疗癌症和其它疾病或病症的医药组合物
CN201410112836.0A Active CN103893186B (zh) 2009-07-31 2010-07-28 用于治疗癌症和其它疾病或病症的医药组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410112836.0A Active CN103893186B (zh) 2009-07-31 2010-07-28 用于治疗癌症和其它疾病或病症的医药组合物

Country Status (30)

Country Link
US (3) US20110039826A1 (enExample)
EP (1) EP2459173B1 (enExample)
JP (2) JP2013500965A (enExample)
KR (1) KR101762285B1 (enExample)
CN (2) CN102548539A (enExample)
AR (1) AR077436A1 (enExample)
AU (1) AU2010276741B2 (enExample)
BR (1) BR112012002265B8 (enExample)
CA (1) CA2769531C (enExample)
CL (1) CL2012000261A1 (enExample)
CO (1) CO6612185A2 (enExample)
CR (1) CR20120084A (enExample)
EA (1) EA025277B1 (enExample)
EC (1) ECSP12011703A (enExample)
GE (1) GEP201606513B (enExample)
IL (1) IL217839A (enExample)
IN (1) IN2012DN01237A (enExample)
JO (1) JO3434B1 (enExample)
MA (1) MA33533B1 (enExample)
MX (2) MX348197B (enExample)
MY (1) MY174084A (enExample)
NZ (1) NZ598096A (enExample)
PE (1) PE20120788A1 (enExample)
SG (2) SG177751A1 (enExample)
TN (1) TN2012000046A1 (enExample)
TW (1) TWI522357B (enExample)
UA (1) UA110463C2 (enExample)
UY (1) UY32822A (enExample)
WO (1) WO2011014248A1 (enExample)
ZA (1) ZA201200944B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005003951T4 (de) * 2004-05-14 2012-10-11 Millennium Pharmaceuticals, Inc. Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
CN102264368B (zh) 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
TWI392514B (zh) * 2010-01-29 2013-04-11 Colgate Palmolive Co 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑
CN104031049A (zh) 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
USD797120S1 (en) 2015-08-28 2017-09-12 Samsung Electronics Co., Ltd. Display screen or portion thereof with graphical user interface
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111039A2 (en) * 2004-05-14 2005-11-24 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2008063525A1 (en) * 2006-11-16 2008-05-29 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
CN100389825C (zh) 1999-08-11 2008-05-28 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
WO2001072300A1 (en) * 2000-03-24 2001-10-04 Baker Norton Pharmaceuticals, Inc. Uses of metal salts to stabilize taxane-based compositions
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
EP1962830B1 (en) * 2005-12-23 2013-03-27 GlaxoSmithKline LLC Azaindole inhibitors of aurora kinases
US20080004286A1 (en) 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
PT2046292E (pt) * 2006-07-21 2010-04-26 Novartis Ag Formulações de éteres benzimidazolil-piridílicos
JP2010500352A (ja) 2006-08-09 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
CN102264368B (zh) * 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN104031049A (zh) * 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111039A2 (en) * 2004-05-14 2005-11-24 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2008063525A1 (en) * 2006-11-16 2008-05-29 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression

Also Published As

Publication number Publication date
WO2011014248A1 (en) 2011-02-03
SG10201404483VA (en) 2014-10-30
CL2012000261A1 (es) 2012-08-03
CA2769531A1 (en) 2011-02-03
JP6014695B2 (ja) 2016-10-25
TWI522357B (zh) 2016-02-21
EA201270205A1 (ru) 2012-07-30
US20160158244A1 (en) 2016-06-09
KR101762285B1 (ko) 2017-07-28
IL217839A0 (en) 2012-03-29
JP2013500965A (ja) 2013-01-10
US9127011B2 (en) 2015-09-08
NZ598096A (en) 2014-05-30
AU2010276741A1 (en) 2012-03-01
MY174084A (en) 2020-03-09
BR112012002265B8 (pt) 2021-05-25
UA110463C2 (ru) 2016-01-12
CA2769531C (en) 2017-11-07
TN2012000046A1 (en) 2013-09-19
KR20120053008A (ko) 2012-05-24
CR20120084A (es) 2012-06-01
JO3434B1 (ar) 2019-10-20
TW201107331A (en) 2011-03-01
PE20120788A1 (es) 2012-07-22
ECSP12011703A (es) 2012-03-30
EP2459173A1 (en) 2012-06-06
US20110039826A1 (en) 2011-02-17
SG177751A1 (en) 2012-02-28
CN103893186A (zh) 2014-07-02
US20140073630A1 (en) 2014-03-13
AR077436A1 (es) 2011-08-24
BR112012002265A2 (pt) 2016-06-14
ZA201200944B (en) 2015-07-29
EA025277B1 (ru) 2016-12-30
IN2012DN01237A (enExample) 2015-05-15
JP2015091877A (ja) 2015-05-14
MX348197B (es) 2017-06-05
EP2459173B1 (en) 2018-02-28
US9504693B2 (en) 2016-11-29
CO6612185A2 (es) 2013-02-01
MA33533B1 (fr) 2012-08-01
UY32822A (es) 2011-01-31
MX2012001196A (es) 2012-03-14
IL217839A (en) 2017-01-31
BR112012002265B1 (pt) 2021-01-12
CN103893186B (zh) 2019-07-09
AU2010276741B2 (en) 2016-07-14
GEP201606513B (en) 2016-07-25

Similar Documents

Publication Publication Date Title
CA2769531C (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
CN108289959B (zh) 用于治疗脊髓性肌萎缩的组合物
US20030109515A1 (en) Pharmaceutical formulation of a platinum derivative
KR20180113976A (ko) 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
JP2023029899A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
US20170056336A1 (en) Co-targeting androgen receptor splice variants and mtor signaling pathway for the treatment of castration-resistant prostate cancer
JP2016020356A (ja) 過増殖性疾患、自己免疫疾患、および心疾患の治療のための３−キヌクリジノンを含有する水溶液
IL276838A (en) Oral formulation and suspension of an oncology drug
CN107613984A (zh) 药物组合物及其用途
HK1172242A (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
HK1172242B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
WO2005044257A1 (en) Discodermolide compositions
HK1072002B (en) Platinum derivative pharmaceutical formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120704